araag2/HINT huggingface dataset:
Clinical trial NCT02783599 (phase 1, status: completed)
Conditions: soft tissue sarcoma
ICD codes: C46.1
Drugs: olaratumab, doxorubicin
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a histologically confirmed diagnosis of STS for which olaratumab and doxorubicin
             would be appropriate therapy. Participants with a diagnosis of Grade 1 liposarcoma are
             eligible if there is histological or radiographic evidence of evolution to more
             aggressive disease. Participants with Kaposi's sarcoma and gastrointestinal stromal
             tumors (GIST) will be excluded. Participants must have potentially resectable disease
             (as assessed by the study investigator) and have a primary tumor lesion deemed
             amenable to serial biopsy.

          -  For radiotherapy addendum only: Have a histologically confirmed diagnosis of STS of
             the extremities, Grade 2 or 3, >5 centimeters, for which olaratumab and radiotherapy
             would be appropriate therapy. Participants with Kaposi's sarcoma, GIST or myxoid
             liposarcoma will be excluded.

          -  Have consented to undergo mandatory serial peripheral whole blood and tumor tissue
             sampling.

        Exclusion Criteria:

          -  Have active central nervous system (CNS) or leptomeningeal metastasis (brain
             metastasis) at the time of enrollment. Participants with a history of a CNS metastasis
             previously treated with curative intent (for example, stereotactic radiation or
             surgery) that have not progressed on follow-up imaging, have been asymptomatic for at
             least 60 days and are not receiving systemic corticosteroids and or/anticonvulsants,
             are eligible. Participants with signs or symptoms of neurological compromise should
             have appropriate radiographic imaging performed before enrollment to rule out brain
             metastasis.

          -  Have received prior treatment with doxorubicin, epirubicin, idarubicin, and/or other
             anthracyclines or anthracenediones; the participant has received treatment with
             olaratumab or has participated in a prior olaratumab trial.

          -  For radiotherapy addendum only: Have received previous radiotherapy in the primary
             tumor lesion and/or prior treatment with olaratumab or has participated in a prior
             olaratumab trial.
Clinical trial NCT02801487 (phase 1/phase 2, status: terminated)
Conditions: nasopharyngeal carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: cisplatin
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    slow accrual of patients.
  
Eligibility criteria:

        Inclusion Criteria:

          -  -Pathologically confirmed NPC

          -  Completed a definitive course of intensity-modulated photon radiation therapy (IMXT)
             to a total dose of ≥ 66 Gy

          -  Recurrence diagnosed more than 12 months after the initial course of IMXT

          -  Age ≥ 18 and < 70 years of age

          -  Karnofsky Performance Score ≥70

          -  Willing to accept adequate contraception for women with childbearing potential

          -  Ability to understand character and individual consequences of the clinical trial

          -  Willing to sign the written informed consent; Informed consent must be signed before
             the enrollment in the trial

        Exclusion Criteria:

          -  Local recurrence of NPC diagnosed within 12 months from the completion of previous
             course of radiation therapy

          -  Presence of distant metastasis

          -  Technology used other than IMXT (including brachytherapy following IMXT) for the
             treatment of initial diagnosis of NPC

          -  Pregnant or lactating women

          -  Patients who have not yet recovered from acute toxicities of prior therapies

          -  A diagnosis of malignancy other than CIS of the cervix, BCC and SCC of the skin within
             the past 5 years

          -  Refusal of the patient to participate into the study
Clinical trial NCT02809183 (phase 1/phase 2, status: completed)
Conditions: acidosis
ICD codes: E87.2, P74.0
Drugs: placebo, trc101
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Estimated glomerular filtration rate (eGFR) of 20 to <60 mL/min/1.73m2

          -  Serum bicarbonate level of 12 to 20 mEq/L

        Exclusion Criteria:

          -  Any level of low serum bicarbonate that, in the opinion of the Investigator, requires
             emergency intervention.

          -  Severe comorbid conditions other than chronic kidney disease.

          -  Chronic obstructive pulmonary disease.

          -  Anticipated changes in doses of any of the following drugs or drug classes: diuretics,
             non-ophthalmic carbonic anhydrase inhibitors, oral diabetes drugs, antihypertensive
             drugs, antacids, H2-blockers, or proton pump inhibitors.

          -  Excluded drugs or drug classes: insulin, non-daily or "as needed" diuretics, herbal
             products, dietary supplements, multivitamins, naturopathic remedies, sodium
             bicarbonate, potassium citrate, sodium citrate or other alkali therapy, non-steroidal
             anti-inflammatory drugs (NSAIDs), fiber supplements, laxatives, calcium and magnesium
             supplements, or electrolyte binders and other binder drugs.
Clinical trial NCT02815488 (phase 1/phase 2, status: terminated)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: chf6297 (part 1 - sad), placebo (part 1 - sad), chf6297 (part 2 - mad), placebo (part 2 - mad), chf6297 (part 3), placebo (part 3), chf6297 (part 4), placebo (part 4)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    very poor recruitment in the part 4 of the study
  
Eligibility criteria:

        Inclusion criteria:

        Part 1, Part 2, Part 4 (Healthy subjects):

          -  Male subjects aged 18-55 years;

          -  Non smokers

          -  Lung function above 80% of predicted normal value

          -  Healthy subjects based on medical evaluation including medical history, physical
             examination, laboratory tests and cardiac testing

          -  ability to produce an adequate induced sputum sample (study part 4 only)

        Part 3 (COPD patients):

          -  Males and females aged 40-75 years

          -  Current or past smokers

          -  stable patients with a post-bronchodilator FEV1 between 40 and 80% of predicted normal
             value and FEV1/FVC ratio <0.7

          -  Ability to produce a spontaneous and an adequate induced sputum sample

        Exclusion Criteria:

        Parts 1,2, 4 (Healthy subjects):

          -  Any clinically relevant abnormalities and/or uncontrolled diseases

          -  Abnormal laboratory values

          -  Recent respiratory tract infection

          -  Hypersensitivity to the drug or excipients

          -  Positive serology results

          -  Positive cotinine, alcohol, drug of abuse tests

        Part 3 (COPD patients):

          -  Females of childbearing potential

          -  History of asthma

          -  Unstable concomitant diseases

          -  Abnormal relevant Holter ECG parameters

          -  Recent acute exacerbations of COPD or respiratory tract infection

          -  Hypersensitivity to the drug or excipients

          -  Positive serology results
Clinical trial NCT02815540 (phase 1/phase 2, status: terminated)
Conditions: lennox-gastaut syndrome, dravet syndrome
ICD codes: G40.813, G40.814, G40.811, G40.812, G40.833, G40.834
Drugs: cannabidiol
SMILES: CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
Reason stopped: 
    investigator on medical leave, and difficult recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with Dravet syndrome or Lennox-Gastaut syndrome

          -  Patients who are planning to obtain medical cannabidiol

          -  Patients who are already taking medical cannabidiol and are planning to stop taking it

        Exclusion Criteria:

          -  Patients without a diagnosis of Dravet syndrome or Lennox-Gastaut syndrome
Clinical trial NCT02818348 (phase 1, status: completed)
Conditions: hiv-1 infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: darunavir/cobicistat, etravirine
SMILES: CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1, CC1=CC(=CC(C)=C1OC1=C(Br)C(N)=NC(NC2=CC=C(C=C2)C#N)=N1)C#N
Eligibility criteria:

        Inclusion Criteria:

          1. Age ≥18 years old

          2. Documented HIV infection (western blot)

          3. Stable antiretroviral treatment including darunavir/cobicistat 800/150mg QD (cohort
             DRV) or etravirine 400mg QD (cohort ETR) for at least 4 weeks. Plasma HIV-1 RNA load
             <50 copies/mL for at least 12 weeks

          4. In women of childbearing age*, commitment to use at least one of these birth control
             methods: male or female condom with or without spermicide, cap, diaphragm or sponge
             with or without spermicide, intrauterine device, bilateral tubal occlusion,
             vasectomised partner, sexual abstinence during the study.

          5. Signed Informed Consent

               -  According to recommendations of Clinical Trial Facilitation Group (CTFG), a woman
                  is considered of childbearing potential: fertile, following menarche and until
                  becoming post-menopausal unless permanently sterile. Permanent sterilisation
                  methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

        Exclusion Criteria:

          1. Inadequate adherence to antiretroviral treatment (<90% during the last week)

          2. Patients who are taking or have been taking any other medication within the last two
             weeks prior to be recruited in the study, including herbal medicines and food
             supplements, with known interactions with darunavir, cobicistat or etravirine (i.e St.
             John's wort, grapefruit juice, some antibiotics such as erythromycin or rifampicin;
             antiepileptics such as phenytoin, phenobarbital or carbamazepine; antifungals such as
             itraconazole or ketoconazole; antiretrovirals such as ritonavir, efavirenz or
             nevirapine, among others.)

          3. Acute illness that could interfere with darunavir, cobicistat or etravirine
             pharmacokinetics (acute hepatitis…) within the prior 4 weeks

          4. Active AIDS-defining illness within the prior 4 weeks

          5. In women, pregnancy or breastfeeding.

          6. Evidence or clinical suspicion that the patient will not be able to complete the study
             treatment and protocol
Clinical trial NCT02824536 (phase 1, status: completed)
Conditions: human immunodeficiency virus
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: 3bnc117, 10-1074, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females, age 18 to 65.

          -  Amenable to HIV risk reduction counseling and agrees to maintain behavior consistent
             with low risk of HIV exposure.

          -  If sexually active male or female, and participating in sexual activity that could
             lead to pregnancy, agrees to use two effective methods of contraception (i.e. condom
             with spermicide, diaphragm with spermicide, hormone-eluting IUD, hormone-based
             contraceptive with condom) for the duration of the study.

        Exclusion Criteria:

          -  Confirmed HIV-1 or HIV-2 infection.

          -  History of immunodeficiency or autoimmune disease; use of systemic corticosteroids,
             immunosuppressive anti-cancer, or other medications considered significant by the
             trial physician within the last 6 months.

          -  Any clinically significant acute or chronic medical condition (such as autoimmune
             diseases) that in the opinion of the investigator would preclude participation.

          -  Within the 12 months prior to enrollment, the participant has a history of sexually
             transmitted infection.

          -  Chronic Hepatitis B or Hepatitis C infection.

          -  Laboratory abnormalities in the parameters listed:

          -  Absolute neutrophil count ≤ 2,000;

          -  Hemoglobin ≤ 12 gm/dL if female; ≤ 13.5 gm/dL if male;

          -  Platelet count ≤ 125,000;

          -  Alanine Aminotransferase (ALT) ≥ 1.25 x ULN; Aspartate Aminotransferase (AST) ≥ 1.25 x
             ULN;

          -  Alkaline phosphatase ≥ 1.5 x ULN

          -  Total bilirubin > 1.0 x ULN;

          -  Creatinine ≥1.1 x ULN;

          -  Pregnancy or lactation.

          -  Any vaccination within 14 days prior to infusion

          -  Receipt of any experimental HIV vaccine in the past.

          -  History of severe reaction to a vaccine or drug infusion or history of severe allergic
             reactions.

          -  Participation in another clinical study of an investigational product currently or
             within past 12 weeks, or expected participation during this study.
Clinical trial NCT02826798 (phase 1, status: completed)
Conditions: cytomegalovirus infections
ICD codes: P35.1
Drugs: vbi-1501a 0.5 μg, vbi-1501a 1.0 μg, vbi-1501a 2.0 μg, vbi-1501 1.0 μg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Generally healthy adult female and male 18 to 40 years of age, inclusive;

          2. Serologically confirmed to be CMV seronegative at screening;

          3. Female volunteers must agree to use an adequate contraception method as deemed
             appropriate by the investigator

          4. Sign an informed consent document indicating understanding of the purpose and
             procedures required for the study and willingness to participate in the study

        Exclusion Criteria:

          1. History of or current clinically significant medical illness or any other illness that
             in the opinion of the investigator interferes with the interpretation of the study
             results

          2. Clinically significant abnormal physical examination, vital signs, or clinically
             significant abnormal values for hematology, clinical chemistry or urinalysis at
             screening as determined by the investigator

          3. Previous receipt of any cytomegalovirus vaccine

          4. History of allergic reactions or anaphylactic reaction to any vaccine component

          5. Pregnant or breastfeeding or plans to conceive from two weeks before the study start
             through six months after the last dose of study vaccine

          6. Known or suspected impairment of immunological function, including but not limited to
             autoimmune diseases, splenectomy, or HIV/AIDS

          7. Chronic administration (defined as more than 14 days in total) of immune-suppressive
             or other immune-modifying drug with six months prior to the product dose (for
             corticosteroids, this is defined as prednisone ≥20 mg/day or equivalent). Inhaled and
             topical steroids are allowed

          8. Participation in another clinical study within 30 days or plans to participate in
             another treatment based clinical study during the conduct of the present study

          9. Any skin abnormality or tattoo that would limit post-vaccination injection site
             assessment

         10. Any history of cancer requiring chemotherapy or radiation within 5 years of
             randomization or current disease

         11. Are family members of study center staff
Clinical trial NCT02830542 (phase 1, status: unknown status)
Conditions: clostridium difficile infection
ICD codes: A05.2, A04.71, A04.72, B96.7
Drugs: ser-262, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Signed informed consent, indicating that the subject understands the purpose of and
             procedures required for the study.

          2. Male or female subjects ≥ 18 years.

          3. A primary (first) episode of CDI with documentation of the episode including CDI date,
             test results, antibiotic treatment (including start and stop dates), and response to
             treatment

        Exclusion Criteria:

          1. Females who are pregnant, breastfeeding, lactating, or planning to become pregnant
             during the study.

          2. Known or suspected toxic megacolon and/or known small bowel ileus.

          3. Active irritable bowel syndrome with diarrhea within the previous 12 months.

          4. Major gastrointestinal surgery (eg, significant bowel resection or diversion) within 3
             months before enrollment (this does not include appendectomy or cholecystectomy) or
             any history of total colectomy or bariatric surgery.

          5. History of inflammatory bowel disease (ulcerative colitis, Crohn's disease,
             microscopic colitis) with diarrhea believed to be caused by active inflammatory bowel
             disease in the past 12 months.

          6. Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2

          7. Admitted to or expected to be admitted to an intensive care unit for medical reasons
             (not just boarding). Patients discharged from an intensive care unit before Day 1 may
             be enrolled.

          8. Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for
             active malignancy (patients on maintenance chemotherapy may only be enrolled after
             consultation with medical monitor).

          9. Absolute neutrophil count < 500 cells/mm3
Clinical trial NCT02856750 (early phase 1, status: completed)
Conditions: acute pain
ICD codes: G89.12, G89.18, G89.11, G89.3
Drugs: gabapentin
SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  > 1 rib fractures

          -  Requiring hospital admission

          -  Enrolled within 24 hours of injury

        Exclusion Criteria:

          -  Pregnancy

          -  Intubation

          -  Age <18, age >65

          -  Inability to tolerate PO medication

          -  Patient refusal

          -  Inability to obtain consent from patient or surrogate

          -  Renal or Hepatic impairment

          -  Allergy or Hypersensitivity to gabapentin or any component of the formulation
Clinical trial NCT02862145 (phase 1/phase 2, status: withdrawn)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: mrx34, dexamethasone
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Reason stopped: 
    5 immune related serious adverse events in phase 1 study
  
Eligibility criteria:

        Inclusion Criteria:

          -  ≥18 years of age

          -  Advanced or metastatic cutaneous, acral or mucosal melanoma

          -  Tumor lesions accessible to serial biopsies

          -  ECOG ≤ 1

          -  ANC ≥, Plts ≥100,000 /mm3

        Exclusion Criteria:

          -  Serious active non-malignant disease

          -  Central Nervous System metastasis
Clinical trial NCT02864264 (phase 1, status: terminated)
Conditions: healthy volunteers, ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: bms-986184, placebo matching bms-986184
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    adverse change in the risk/benefit
  
Eligibility criteria:

        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Women of childbearing potential must have a negative serum pregnancy test within 24
             hours prior to the start of study drug

          -  Diagnosis of ulcerative colitis confirmed by endoscopic and histologic evidence (if no
             previous confirmation of diagnosis is available or if diagnosis is not conclusive, at
             time of baseline endoscopy, histology must be performed and read locally to confirm
             diagnosis)

        Exclusion Criteria:

          -  Any bacterial, fungal or viral infection, including tuberculosis, HIV, hepatitis B or
             hepatitis C

          -  Subjects with history of cancer, lymphoproliferative disease, class III or IV
             congestive heart failure, myocardial infarction, unstable angina pectoris, or any
             history of significant ocular disease such as glaucoma or retinal disease

        Other protocol defined inclusion/exclusion criteria could apply
Clinical trial NCT02865538 (phase 1/phase 2, status: completed)
Conditions: post-menopausal vasomotor symptoms
ICD codes: J30.0
Drugs: bay3427080, placebo (for bay3427080)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Post-menopausal female subjects experiencing frequent moderate to severe hot
             flashes.Menopause will be defined as:

               -  12 months of spontaneous amenorrhea;

               -  OR at least 6 weeks' post-surgical bilateral oophorectomy with or without
                  hysterectomy.

        Exclusion Criteria:

          -  BMI > 35kg/m2.

          -  Any active comorbid disease, ECG or laboratory result deemed by the investigator to be
             clinically significant and which could impact safety during study conduct or that
             could interfere with the study evaluation, procedures or completion.

          -  Use of prohibited medications defined in the protocol.

          -  Inability or unwillingness to comply with study procedures or requirements.